|
|
|
|
| LEADER |
02101nam a2200241 u 4500 |
| 001 |
EB002002033 |
| 003 |
EBX01000000000000001164934 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
210907 r ||| eng |
| 245 |
0 |
0 |
|a Pharmacoeconomic review report: Savuconazole (Cresemba) (AVIR pharma inc.)
|h Elektronische Ressource
|
| 246 |
3 |
1 |
|a Savuconazole (Cresemba) (AVIR pharma inc.)
|
| 260 |
|
|
|a Ottawa (ON)
|b CADTH
|c June 2019, 2019
|
| 300 |
|
|
|a 1 PDF file (38 pages)
|b illustrations
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 710 |
2 |
|
|a CADTH Canadian Drug Expert Committee
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH common drug review
|
| 500 |
|
|
|a "Version: final."
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK543386
|3 Volltext
|
| 082 |
0 |
|
|a 330
|
| 520 |
|
|
|a Isavuconazole (Cresemba) is an azole antifungal drug indicated for the treatment of invasive aspergillosis (IA) and invasive mucormycosis (IM) in adults. It is available in powder form for intravenous (IV) administration and in capsule form for oral use. A vial for IV administration contains 200 mg of isavuconazole, priced at $400, while an oral capsule contains 100 mg of isavuconazole, priced at $78.83. Treatment is initiated with a loading dose of 200 mg every eight hours for six doses (48 hours) followed by a maintenance dose of 200 mg daily. Clinical experts recommend a minimum of 6 to 12 weeks of treatment for IA, while achieving a favourable clinical response in IM will take several weeks. At the manufacturer's submitted price, the daily cost for the loading dose is $472.98 for the oral formulation and $1,200 for the IV formulation. The daily cost for the maintenance dose is $157.66 for the oral formulation and $400 for the IV formulation. Based on CADTH's calculations, an eight-week treatment course will cost $9,460 using the oral formulation and $24,000 using the IV formulation. The manufacturer submitted a cost-utility analysis comparing isavuconazole with voriconazole in patients with suspected IA.
|